Newsroom


Please note that the Company does not update, correct or revise news releases after they have been issued. For the most current information about the Company, please refer to the most recent releases.

4/29/2019, Monday

Media Contact:
Kristy Marks
Kristy.marks@bausch.com
(908) 927-0683

Teresa Panas
teresa@tgpcomm.com
(973) 809-8590

BAUSCH + LOMB INVITES SURGEONS TO NEW IN-BOOTH EXPERIENCE EXCHANGE™, EVENTS AND SCIENTIFIC PRESENTATIONS DURING THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY

BRIDGEWATER, N.J., Apr. 29, 2019 – Bausch + Lomb, a leading global eye health company, today announced that it will hold the company’s first in-booth #ExperienceExchange where surgeons will have the opportunity to join internationally recognized surgeons in a one-on-one session in the Bausch + Lomb booth (#1521) during the Annual Meeting of the American Society of Cataract and Refractive Surgery in San Diego (May 3-7).

“We understand how important it is for our customers to have the chance to discuss their surgical experiences with their peers, particularly as they explore new technologies that may be right for them and their patients,” said Chuck Hess, vice president and general manager, U.S. Surgical, Bausch + Lomb. “Our intention is to provide a forum where our customers can hear firsthand from these well-respected surgeons the impressive results they are experiencing with our portfolio as a result of our continued commitment and investment in delivering products that address the needs of patients.”

During the one-on-one #ExperienceExchange, surgeons will be able to discuss best-practices, learn from the experiences of their peers and get more clinical insight into several of Bausch + Lomb’s latest surgical technologies, including the company’s latest IOL technologies, the enVista® MX60E with Stableflex™ technology, and the enVista toric MX60T. The enVista IOLs remain the only single-piece, hydrophobic acrylic lenses domestically available that has been proven to be glistening-free.1

Surgeons can also discuss the features of the company’s next-generation phacoemulsification platform, the Stellaris Elite® vision enhancement system, which offers cataract and retina capabilities in a single platform. One of the newest features is eyeTELLIGENCE, an IBM cloud-based infrastructure exclusive to Stellaris Elite designed to help surgeons and surgical facilities work more efficiently when using the platform.

Other technologies featured in the Bausch + Lomb #ExperienceExchange include the VICTUS® femtosecond laser platform and the Crystalens® AO and Trulign® toric IOLs. To schedule an appointment, surgeons can register online at www.surgeonexperienceexchange.com.

Featured Events
Friday, May 3
“enVista® Toric – Clearly Focused on Changing the OR* Experience with Toric IOLs” 7:00-9:00 p.m. at Donovan’s Steak & Chop House - 570 K Street, San Diego, CA 92101 During the program, Sheri Rowen, M.D., and Mitchell Jackson, M.D., will share their experiences using the company’s first hydrophobic acrylic intraocular lens for astigmatism correction, the enVista MX60T. Attendees are asked to register in advance at www.eveningwithastigmatism.com.

Saturday, May 4
“Complex Cataract Cases: Learn with the Experts” 6:30-9:30 p.m. at Del Frisco’s Double Eagle Steakhouse - 901 Bayfront Court, Suite 105, San Diego, CA 92101 Throughout the evening, Mitchell Jackson, M.D., and Paul Singh, M.D., will present four complex cataract cases, focusing on various attributes of Bausch + Lomb’s extensive surgical and pharmaceutical portfolio. Attendees are asked to register in advance at http://www.reviewofophthalmology.com/CataractCasesASCRS2019.

Sunday, May 5
“Frontiers in Intra-Operative Big Data & IOL Technology for Astigmatism Management” 5:15-6:15 p.m. at the San Diego Convention Center - Ballroom 20D, EyeWorld Theater 2 Program chair Inder Paul Singh, M.D., and faculty, Zaina Al-Mohtaseb, M.D., Neel R. Desai, M.D., and Karoline Rocha, M.D., Ph.D, will discuss how surgeons can address the needs of their astigmatic patients today utilizing the advancements currently available in Bausch + Lomb’s Surgical portfolio. Attendees are asked to register in advance at meetings.eyeworld.org/bausch.

“Discover VYZULTA® (latanoprostene bunod ophthalmic solution), 0.24%” 6:30-9:30 p.m. at Del Frisco’s Double Eagle Steakhouse - 901 Bayfront Court, Suite 105, San Diego, CA 92101 Shan Lin, M.D., will share an overview of the novel mechanism of action for VYZULTA, clinical trial results and insights via case-based examples in glaucoma management. To register in advance, attendees can visit www.reviewofophthalmology.com/VyzultaASCRS2019.

“enVista® Toric – Clearly Focused on Changing the OR* Experience with Toric IOLs” 7-9 at Route 29 restaurant (644 Fifth Avenue, San Diego, CA 92101) An encore presentation, Mitchell Schultz, M.D., and Marjan Farid, M.D., will discuss their personal experience using the Bausch + Lomb enVista Toric IOL. To register for this event in advance, surgeons can visit www.eveningwithastigmatism.com.
*Not quality of vision OR rotational stability, but both

Poster and Podium Presentations
During the meeting, 23 podium presentations and three posters will feature Bausch + Lomb’s surgical and pharmaceutical advancements. The full schedule includes:

Premium IOLs

  • Betts, C et al. “Comparison of Clinical Outcomes of New Monofocal Toric IOL Versus Nontoric Control in Subjects with Mild-to-Moderate Corneal Astigmatism.” San Diego Convention Center, Upper Level Room 1B, on Monday, May 6 from 10:37 to 10:42 a.m.
  • Feinerman, G et al. “Long Term Outcomes on Novel Aberration Neutral Hydrophobic Acrylic Toric IOL Implanted in Subjects with Cataracts and Corneal Astigmatism.” San Diego Convention Center, Upper Level Room 1B, on Sunday, May 5 from 1:43 to 1:48 p.m.
  • Gira, J et al. “Evaluation of Rotational and Centration Stability of New Single-Piece Hydrophobic Acrylic Toric IOL.” San Diego Convention Center, Upper Level Room 1B, on Sunday, May 5 from 1:02 to 1:07 p.m.
  • Mah, F. “Rotational Stability of Aberration Neutral Hydrophobic Acrylic Monofocal IOL with Enhanced Material.” Poster available Saturday, May 4 to Tuesday, May 7.
  • Packer, M et al. “Capacity for a Novel Toric Algorithm to Improve Outcomes in Low-Cylinder Patients Implanted with Nontoric IOLs.” San Diego Convention Center, Upper Level Room 1B, on Sunday, May 5 from 2:11 to 2:16 p.m.
  • Packer, M et al. “Impact of Rotation and Decentration of Low Cylinder Toric IOLs: Comparison between Aberration Neutral and Negatively Aberrated Toric IOLs.” San Diego Convention Center, Upper Level Room 1B, on Sunday, May 5 from 1:30 to 1:35 p.m.
  • Packer, M et al. “Validation of a Comprehensive Toric Calculator and its Capacity to Improve Refractive Outcomes in Toric Subjects.” San Diego Convention Center, Upper Level Room 1B, on Sunday, May 5 from 2:06 to 2:11 p.m.
  • Rooney, D et al. “The Effect of Capsular Tension Rings on Accommodating Intraocular Lens Outcomes.” San Diego Convention Center, Upper Level Room 5B, on Monday, May 6 from 9:03 to 9:08 p.m.
  • Sadri, E et al. “Comparative Assessment of New Enhanced Injector for Plate-Haptic Accommodating Intraocular Lens.” Poster available Saturday, May 4 to Tuesday, May 7.
  • Schultz, M et al. “Early Experience in Patients Implanted with a Single Piece, Toric, Zero Spherical Aberration IOL Objectively Evaluated with Ray Tracing Analyzer and Subjective Patient Vision Assessment Questionnaire.” San Diego Convention Center, Upper Level Room 1B, on Sunday, May 5 from 1:38 to 1:43 p.m.
  • Stephenson, D. “Achieving Astigmatism Correction with New Spherical Aberration Neutral Monofocal Toric IOL with Intraoperative Wavefront Aberrometry.” San Diego Convention Center, Upper Level Room 1B, on Saturday, May 4 from 2:16 to 2:21 p.m.

 

Monofocal IOLs and Delivery Systems

  • Feulner, L. “Evaluation of Postoperative Aberration Profile with Aberration-Neutral Monofocal IOL in Relation to Visual Acuity and Positional Stability.” San Diego Convention Center, Upper Level Room 1A, on Sunday, May 5 from 1:27 to 1:32 p.m.
  • Jackson, M et al. “Femtosecond Laser-Assisted Implantation of Aberration-Neutral One-Piece Hydrophobic Acrylic IOL with Enhanced Material.” San Diego Convention Center, Upper Level Room 1A, on Saturday, May 4 from 1:17 to 1:22 p.m.
  • Liang, E et al. “Comparative Clinical Evaluation of Aberration-Neutral Versus Negatively Aberrated Hydrophobic Acrylic Monofocal IOLs.” San Diego Convention Center, Upper Level Room 1A, on Sunday, May 5 from 1:22 to 1:27 p.m.
  • Liang, E et al. “Validation of Defocus Tolerance of Novel Aberration-neutral Hydrophobic Acrylic Monofocal IOL.” San Diego Convention Center, Upper Level Room 1A, on Saturday, May 4 from 1:48 to 1:53 p.m.
  • Mah, F. “Uncorrected Near-Vision Comparisons of 2 Aspheric Monocular Intraocular IOLs for Cataract Surgery.” San Diego Convention Center, Upper Level Room 1A, on Saturday, May 4 from 1:53 to 1:58 p.m.
  • Rocha, K et. al. “Analysis of Static and Dynamic Factors Associated with Pseudoaccommodation in Monofocal Intraocular Lenses.” San Diego Convention Center, Upper Level Room 1A, on Sunday, May 5 from 3:47 to 3:52 p.m.
  • Rocha, K et al. “Subjective and Objective Analysis of Pseudoaccommodation in Aberration-Free, and Negative Spherical Aberration IOLs Using Ray-Tracing Aberrometry.” San Diego Convention Center, Upper Level Room 1A, on Saturday, May 4 from 1:40 to 1:45 p.m.
  • Sadri, E et al. “In-Vitro Comparison of Efficiency of Optic Recovery with One-Piece Hydrophobic Acrylic Intraocular IOLs.” San Diego Convention Center, Upper Level Room 1A, on Saturday, May 4 from 1:02 to 1:07 p.m.
  • Sadri, E et al. “Ex-Vivo Assessment of Wound Dimensions with Next-Generation Preloaded Injector System in Porcine Eyes.” San Diego Convention Center, Upper Level Room 1A, on Saturday, May 4 from 2:26 to 2:31 p.m.
  • Singh, I et al. “Intra Operative Unfolding Time Comparison between Three Common Hydrophobic IOL Platforms.” San Diego Convention Center, Upper Level Room 1A, on Sunday, May 5 from 2:30 to 2:35 p.m.
  • Stephenson, D. “Objective and Subjective Assessment of Functional-Range-of-Vision in Patients Implanted with Aberration-Free Monofocal IOL.” San Diego Convention Center, Upper Level Room 1A, on Saturday, May 4 from 1:35 to 1:40 p.m.

 

Femtosecond Laser-Assisted Cataract Surgery (FLACS)

  • Bowden, F et al. “Improved Outcomes with Femtosecond Laser-Assisted Arcuate Incisions and Plate-Haptic Toric IOLs to Correct Presbyopia and Astigmatism.” San Diego Convention Center, Upper Level Room 5B, on Monday, May 6 from 8:48 to 8:53 a.m.

 

Phacoemulsification Surgery

  • Schultz, M et al. “Comparative Analysis of Dual Linear Venturi Phacoemulsification with Adaptive Fluidics System Using Femtosecond-Assisted Grid Pattern versus Traditional Phaco with Horizontal Chop for Nuclear Disassembly.” San Diego Convention Center, Upper Level Room 7B, on Monday, May 6 from 3:17 to 3:22 p.m.
  • Schultz, M et al. “Comparative Analysis of Dual Linear Venturi Phacoemulsification with Novel Adaptive Fluidics System in Traditional Phacoemulsification over Various Nuclear Densities.” San Diego Convention Center, Upper Level Room 1B, on Monday, May 6 from 3:45 to 3:50 p.m.

 

Pharmaceuticals

  • LoBue, T et al. “Patient-Reported Outcomes in Clinical Studies of Loteprednol Etabonate (Submicron) Gel 0.38% for the Treatment of Pain and Inflammation Following Cataract Surgery.” Poster available Saturday, May 4 to Tuesday, May 7.

 

Important Safety Information about VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%

INDICATION
VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

Please see full prescribing information at www.bausch.com/vyzulta.

 

Important Safety Information about LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38%

INDICATION
LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38% is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.

IMPORTANT SAFETY INFORMATION

  • LOTEMAX® SM, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.
  • Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If LOTEMAX® SM is used for 10 days or longer, IOP should be monitored.
  • Use of corticosteroids may result in posterior subcapsular cataract formation.
  • The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those with diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.
  • Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infections.
  • Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).
  • Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal cultures should be taken when appropriate.
  • Contact lenses should not be worn when the eyes are inflamed.
  • There were no treatment-emergent adverse drug reactions that occurred in more than 1% of subjects in the three times daily group compared to vehicle.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for Prescribing Information for LOTEMAX® SM.

Important Safety Information about enVista® toric IOL (Model MX60T)

INDICATIONS: Indicated for primary implantation in the capsular bag of the eye in adult patients for the visual correction of aphakia in adult patients and corneal astigmatism following removal of a cataractous lens for improved uncorrected distance vision.

WARNINGS: Physicians considering lens implantation in patients with pre-existing conditions, or in the event of surgical difficulties at the time of cataract extraction, should weight the potential risk/benefit ratio. Rotation of enVista toric® IOL away from the intended axis can reduce the astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder.

PRECAUTIONS: Do not attempt to resterilize this lens. Do not use if the packaging is damaged or if there are signs of leakage. Do not store lenses at temperatures over 43°C (110°F) or lower than 0°C (32°F). Do not reuse the lens. Safety and effectiveness of the enVista toric IOL have not been substantiated in patients with conditions and intraoperative complications as outlined in the enVista toric IOL Directions for Use.

ADVERSE EVENTS: As with any surgical procedure, risk is involved. Potential adverse events accompanying cataract or implant surgery may include, but are not limited to, the following: corneal endothelial damage, infection (endophthalmitis), retinal detachment, vitritis, cystoid macular edema, corneal edema, pupillary block, cyclitic membrane, iris prolapse, hypopyon, transient or persistent glaucoma, acute corneal decompensation, toxic anterior segment syndrome (TASS). Secondary surgical interventions include, but are not limited to: lens repositioning, lens replacement, vitreous aspiration or iridectomy for pupillary block, wound leak repair, and retinal detachment repair.

CAUTION: Federal law restricts this device to sale by or on the order of a physician.

ATTENTION: This is not all you need to know. Please refer to the Directions For Use labeling for a complete listing of indications, full risk and safety information, clinical study information, etc.

About Bausch + Lomb
Bausch + Lomb, a division of Bausch Health, is a leading global eye health organization that is solely focused on helping people see. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries. For more information, visit www.bausch.com.

References
1. Bausch + Lomb. enVista® Toric IOL DFU.

###

®/TM are trademarks of Bausch & Lomb Incorporated or its affiliates.
Any other product/brand names are trademarks of the respective owners
© 2019 Bausch & Lomb Incorporated.
MTB.0198.USA.19

 

 

Print

Number of views (1078)/Comments (0)

x